Kornimate/medical-research-clean huggingface dataset:
avoiding cardiac toxicity in lung cancer patients treated with curative-intent radiotherapy

Conditions: Lung Cancer

Summary: radiotherapy plays a major role in the treatment of lung cancer and recent advances in radiotherapy have led to better cure rates. however, the radiotherapy dose needed to destroy the cancer cells can unfortunately also damage the surrounding organs, such as the heart. the precise mechanism of damage and which areas of the heart are more sensitive to radiation is not currently known. this project uses the analysis of large amounts of existing radiotherapy treatment data to determine this. establishing detailed radiotherapy dose limits for the heart and the heart's sub-structures will lead to the delivery of heart-sparing radiotherapy, where possible, in lung cancer patients treated in yorkshire and greater manchester. the investigators estimate that this should lead to an improvement in one-year survival of approximately 10%.


Eligibility criteria:
inclusion criteria: * histological or clinical diagnosis of lung cancer (stage i-iii non-small cell and small cell lung cancer) suitable for curative-intent radiotherapy * patients suitable for curative-intent radiotherapy (minimum 20 fractions for conventional fractionation and 3-8 fractions for sabr) * life expectancy \> 4 months * age ≥ 18 years * patient has read and understood the participant information sheet and given informed consent exclusion criteria: * no histological or clinical diagnosis of lung cancer (stage i-iii non-small cell and small cell lung cancer) and not suitable for curative-intent radiotherapy * patients not suitable for curative-intent radiotherapy (minimum 20 fractions for conventional fractionation and 3-8 fractions for sabr) * life expectancy \< 4 months * age \< 18 years * patient has not read and understood the participant information sheet and has not given informed consent
compare the effectiveness of sct and pnf in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: this study will evaluate the comparative effectiveness of spider cage therapy (sct) and proprioceptive neuromuscular facilitation (pnf) in managing motor impairments in children with cerebral palsy (cp). cerebral palsy often leads to motor deficits that limit movement and impair functionality.

sct and pnf are therapeutic interventions that target these motor challenges but use distinct approaches. spider cage therapy will involve the use of elastic cords within a supportive frame (the "spider cage") to stabilize the child, enhancing postural control and enabling dynamic movement training. this approach is expected to improve balance and alignment, promoting functional mobility. in contrast, pnf will focus on neuromuscular reeducation through specific movement patterns intended to enhance strength, coordination, and flexibility. by comparing sct and pnf, this study aims to identify their respective impacts on motor function improvements, particularly in gross motor skills, balance, and postural stability, potentially guiding future rehabilitation protocols for children with cp.

Eligibility criteria:
inclusion criteria: * children aged 4-12 years. * clinical diagnosis of cerebral palsy. * classified within gross motor function classification system (gmfcs) levels i to iii. * ability to follow instructions and participate in therapy sessions. exclusion criteria: * severe cognitive impairments hindering participation. * severe musculoskeletal deformities or recent surgeries. * other medical conditions contraindicating participation in physical therapy.
efficacy, safety, tolerability of gefitinib as 1st line in caucasian patients with egfr mutation positive advanced nsclc

Conditions: Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Summary: this study is carried out to see how caucasian patients with lung cancer which has egfr mutation will respond to gefitinib (iressa™) as a first line treatment. safety data will also be collected and analysed to confirm that treatment with gefitinib is safe and well tolerated.

an open label, multicentre, single arm study to characterise the efficacy, safety and tolerability of gefitinib 250 mg (iressa™) as first line treatment in caucasian patients, who have epidermal growth factor receptor (egfr) mutation positive locally advanced or metastatic non-small cell lung cancer

Eligibility criteria:
inclusion criteria: * locally advanced or metastatic non-small cell lung cancer (i.e. cancer that has spread from where it started) which is egfr mutation positive * caucasian female or male patients aged 18 years or over * measurable disease, i.e. at least one lesion, not previously irradiated, as ≥ 10 mm in the longest diameter (≥ 15 mm in short axis for lymph node ) exclusion criteria: * prior adjuvant chemotherapy or other systemic anti-cancer treatment less than 6 month, or palliative radiotherapy less than 4 weeks prior to start of study treatment. * brain metastases or spinal cord compression, unless treated and stable without steroids * any clinically significant illness, which will jeopardize the patients' safety and their participation in the study.

Keywords: gefitinib egfr tki efficacy caucasian patients egfr mutation positive advanced nsclc safety
digital-technology based interventions on treatment of migraine.

Conditions: Migraine; Primary Headache Disorders

Summary: the main aim of the research: to develop an interdisciplinary treatment platform based on digital technology and test the operation and effectiveness of digital interventions in comparison with conventional multidisciplinary treatment or treatment standards (incl. paper diary, nurse counseling, physiotherapy, cognitive-behavioral therapy).

aims and purpose: the main aim of the research: to develop an interdisciplinary treatment platform based on digital technology and test the operation and effectiveness of digital interventions in comparison with conventional multidisciplinary treatment or treatment standards (incl. paper diary, nurse counseling, physiotherapy, cognitive-behavioral therapy). sub-aims: to evaluate the effectiveness of interventions based on digital technology and their impact on the quality of life, comparing them with the interventions or treatment standards performed by ordinary specialists. assess the applicability and accessibility of digital technology-based interventions in the healthcare system against a treatment standard. determine the profile of patients (demographic and clinical indicators). identify restrictions on the use of digital interventions. evaluate patient compliance, non-specific treatment factors such as therapeutic relationship, and treatment credibility against the treatment standard. evaluate patient satisfaction with treatment methods and impact on treatment outcomes. assess the satisfaction of professionals with the implementation of a digital multidisciplinary treatment platform in patients. assess the use and generalization of digitally acquired skills in everyday practice. determine if and how much clinical contact is needed for digital-based interventions to be effective. evaluate cost-effectiveness against the standard of treatment. assess the willingness to pay for the use of an effective headache treatment platform.

Eligibility criteria:
inclusion criteria: 1. diagnosed migraine, frequent episodic, headache days a month 8-14 days; 2. patient age 18-64 years; 3. very good command of the estonian language both orally and in writing. exclusion criteria: 1. headaches lasting less than 8 days and more than 14 days per month; 2. all other primary and/or secondary diagnoses of headache; 3. under the age of 18 or over 64; 4. currently severe depression; 5. psychotic disorders; 6. pregnancy and lactation; 7. severe somatic disease; 8. severe organic mental disorders; 9. other chronic pain; 10. addictive disorders.
investigation of heart failure status over time using respiratory parameters

Conditions: Heart Failure, Congestive; Sleep Apnea Syndromes

Summary: the purpose of the study is to investigate respiratory indicators for clinically important changes in heart failure status over time.


Eligibility criteria:
inclusion criteria: * moderate to severe heart failure (as determined by echocardiogram or by treating physician) exclusion criteria: * malignant disease affecting gas exchange or respiratory parameters * medications compromising breathing with no adverse affects on heart failure * clinically significant (moderate to severe) asthma requiring therapy * chronic parenchymal lung disease (fev1/fvc ratio = 65% or as determined by the treating physician) * severe pulmonary hypertension * heart failure due to alcohol abuse or chemotherapy * narcotic abuse/intravenous drug use (including hiv+ and hepatitis c) * alcohol consumption \> 80g/day * patients receiving home oxygen * methicillin- resistant staphylococcus aureus infection * narcolepsy * cataplexy * enrolled in any concurrent study, that may confound the results of this study. * inability or refusal to sign the patient consent form * inability or refusal to adhere to protocol requirements
high dose radiation therapy with concurrent chemotherapy in locally advanced non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: to assess the efficacy and feasibility of high-dose intensity-modulated radiotherapy with concurrent weekly paclitaxel and cisplatin for patients with locoregionally advanced non-small lung cancer.

local failure remains high in patients with locoregionally advanced non-small lung cancer. given that a biological equivalent dose (bed)more than 100 gy yields approximately a local control rate of 90% in early-stage non-small lung cancer, this bed or ever higher is logically required to control local disease for locally advanced non-small lung cancer. however, dose escalation is limited by radiation-related toxicity. use of hyperfractionated radiation therapy boost to residual metabolic disease as defined by positron emission tomography and computed tomography (pet/ct) immediately after standard chemoradiotherapy (scrt) using image-guided (ig) imrt could potentially improve local control and perhaps survival

Eligibility criteria:
inclusion criteria: * patients must have fdg-avid and histologically or cytologically proven non-small cell lung cancer. * age 1 8-75. * eastern cooperative oncology group （ecog） performance status 0 to 2. * stage iii ( american joint committee on cancer ajcc, 7th ed.). * no prior radiation to the thorax that would overlap with the current treatment field. * adequate bone marrow, renal and hepatic functions as assessed by the following: hemoglobin \>/= 10.0 g/dl, platelet count \>/= 1 00,000/ mm\^3,absolute granulocyte count (agc) ≥2 × 10\^9 cells/l,bilirubin and aspartate transaminase ≤1.5 ×upper limit of normal (uln), creatinine \</ =1 .5 times uln. * a signed informed consent must be obtained prior to therapy. * induction chemotherapy is allowed. * life expectancy more than 3 months exclusion criteria: * patients with any component of small cell lung carcinoma are excluded from this study. * patients with evidence of a malignant pleural or pericardial effusion are excluded. * prior radiotherapy that would overlap the radiation fields. * uncontrolled concurrent illness including, but not limited to: chronic obstructive pulmonary disease(copd) exacerbation or other respiratory illness, serious uncontrolled infection, symptomatic congestive heart failure (chf),unstable angina pectoris, uncontrolled hypertension,or psychiatric illness/social situations that would limit compliance with the study requirements. * known hypersensitivity to paclitaxel. * any other condition or circumstance that would, in the opinion of the investigator, make the patient unsuitable for participation in the study. * conditions precluding medical follow-up and protocol compliance
evaluation of therapeutic strategies in pediatric cataract surgery

Conditions: Cataract

Summary: the purpose of this observational study is to assess the therapeutic strategies in the treatment of pediatric cataracts.

technical progress and recently described potential issues have recently challenged the surgical treatment of pediatric cataracts. many questions remain unsolved: primary vs secondary implantation, nature of the implant used. the aim of this study is to establish a systematic prospective register of all cataracts operated on in a tertiary pediatric centre in order to help answering these questions.

Eligibility criteria:
inclusion criteria: * child cataract surgery from 1 september 2014 in the department of ophthalmology, university hospital necker-enfants malades * children aged between 0 and 17 years * child with unilateral or bilateral cataract exclusion criteria: * child with bilateral cataract, one eye having previously been operated in another center. * children whose parents have notified the doctor their refusal of data collection

Keywords: therapeutic strategies pediatrics cataract surgery intra-ocular lens
relationship between immunity and metabolism in patients receiving immune checkpoint inhibitors for advanced cancer. ( rimec )

Conditions: Metabolism Disorder; Cancer; Immune Checkpoint Inhibitors

Summary: recent ema and fda approvals have made immune checkpoint inhibitors (ici) a standard of care in cancer treatment. ici, used alone or as a combination are now the backbone of renal cell and lung carcinoma treatment. however, a significant proportion of patients does not respond to ici. thus the identification of predictive response factor is a major issue. while factors associated with the tumour and its micro environment have been widely studied, factors associated with the patient such as metabolism could also affect the response to ici and remain poorly studied. the hypothesis of the investigators is that dysmetabolims, via the induction of a chronic inflammatory state could induce a defect of lymphocyte production and activation as well as a modification of the immunogenicity of tumor cells and immune cells infiltration. the consequences could be a decrease in ici response rate as well as an increase in immune related adverse events (iraes). to test this hypothesis, the investigators propose a prospective bi-centric exploratory study including 60 patients treated with ici for advanced lung or renal cell carcinoma. the data collected will be : * clinical (calorimetry, impedancemetry, survey of eating habits, tumour characteristics, epidemiological data), * biologics (baseline and 3-months plasma bio banking for standard biology, inflammation markers tnf- α, il1-6-8-11-17, tgf-ß, tweak, complement study c3, c4, c4d, ch50, c1q, cd46) primary objective is to assess the response to ici depending on metabolic status. secondary objectives are to study the relationships between metabolism / cytokines profile/ complement profile and ici response. the investigators seek to generate hypotheses and to obtain exploratory data before submission of a hospital clinical research program whose objective will be to evaluate the impact of dysmetabolism on overall survival and to characterize immune and anatomopathological profiles (using dna microarrays and flow cytometry techinques) of patients treated with ici for renal cell or lung carcinoma.


Eligibility criteria:
inclusion criteria: * patients ≥18 years * patients receiving immune checkpoint inhibitors, used alone or as a combination with chemotherapy or tyrosine kinase inhibitor or other immune checkpoint inhibitor, for advanced renal cell or lung carcinoma. * patient informed and signed the consent to participate in the research exclusion criteria: * patients with history of auto immune disease * patients enrolled in an interventional study or be in the exclusion period following a previous research, if applicable * patient not affiliated to the social security scheme or under ame * patient under guardianship or curatorship or under legal protection * patient unable or unwilling to give written consent * pregnant patient be in the exclusion period following a previous research, if applicable
pharmacokinetics of apixaban in patients with short bowel syndrome requiring long term parenteral nutrition

Conditions: Short Bowel Syndrome; Anticoagulation

Summary: short bowel syndrome (sbs) is defined as a loss of function of the small intestine resulting in a malabsorptive disorder. in sbs, oral drug absorption may be altered due to extensive intestinal resection. it remains unclear to what extent apixaban exposure is impacted in sbs.therefore this study tries to investigate the pharmacokinetics (pk) of apixaban in adult patients with sbs requiring long-term parenteral nutrition (pn).


Eligibility criteria:
inclusion criteria sbs single dose: - patients with sbs (small bowel length of \ 3 months) pn or fluids who are apixaban-, vitamin k antagonist- and teduglutide naive inclusion criteria sbs steady-state: - patients with sbs (small bowel length of \ 3 months) pn or fluids who are teduglutide naive and who are already taking apixaban 2,5 mg or 5 mg twice daily for ≥ 4 days inclusion criteria non-sbs single dose: - healthy individuals without history of gi resections or other conditions associated with impaired absorption, who are apixaban- and vitamin k antagonist naive inclusion criteria non-sbs steady-state: - patients without history of gastrointestinal resections or other conditions associated with impaired absorption (= controls), who are already taking apixaban 2,5 mg or 5 mg twice daily for ≥ 4 days exclusion criteria sbs (single dose+ steady-state): * \<18 years * non-dutch speaking * recent (\<6 months) major bleeds according with the international society on thrombosis and haemostasis definition of major bleeding in non-surgical patients (20) * creatinine clearance of \< 15 ml/min or dialysis dependent * liver failure classified as child pugh c * total bilirubin ≥ 1.77 mg/dl (= 1,5 x upper limit of normal) * presence of coagulopathy and a clinically relevant bleeding risk * pregnancy or lactation * concomitant intake of strong combined inhibitors of cyp3a4 and p-gp * participation in a recent (\<1 month) trial with an investigational product * recent (\<6 months) gastrointestinal surgery * gastrointestinal mucosal disease interfering with absorption (e.g. radio-enteritis, inflammatory bowel disease, celiac disease, ...) * gastrointestinal fistulae * sbs with intestinal failure resulting from gastric bypass surgery exclusion criteria non-sbs (single dose+ steady-state): * \<18 years * non-dutch speaking * recent (\<6 months) major bleeds according with the international society on thrombosis and haemostasis definition of major bleeding in non-surgical patients (20) * creatinine clearance of \< 15 ml/min or dialysis dependent * liver failure classified as child pugh c * total bilirubin ≥ 1.77 mg/dl (= 1,5 x upper limit of normal) * presence of coagulopathy and a clinically relevant bleeding risk * pregnancy or lactation * concomitant intake of strong combined inhibitors of cyp3a4 and p-gp * use of prokinetics, antimotility drugs or opioids * participation in a recent (\<1 month) trial with an investigational product

Keywords: apixaban pharmacokinetics
protocol for optimizing colonoscopy preparation in patients with inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases

Summary: clinical trial evaluating efficacy of bowel cleansing solutions in patients with inflammatory bowel disease.

simple blind, randomized study evaluating efficacy of 1lpeg vs 2l peg vs 2l sodium picosulfate in bowel cleansing of patients diagnosed of inflammatory bowel disease undergoing diagnostic or follow-up routine colonoscopy.

Eligibility criteria:
inclusion criteria: * patients between 18y and 90y * patients with a diagnosis of ibd undergoing follow-up or screening colonoscopy exclusion criteria: * patients \ 90y * pregnant women * patients with a past history of inadequate bowel cleansing in a colonoscopy performed in the previous 12 months prior to initiation of study * patients with a history of bowel resection * patients undergoing therapeutic colonoscopy * patients unable to understand study protocol

Keywords: colonoscopy inflammatory bowel diseases
risk factors for thrombosis in children with central venous lines

Conditions: Pediatric Venous Thromboembolism

Summary: this project addresses the role of lab markers around the time of central line placement in predicting risk of thrombosis in pediatric patients with central venous lines being placed. the project proposes an innovative way to predict higher risk of thrombosis in the pediatric population to give clinicians a valid tool to guide clinical practice for these patients.


Eligibility criteria:
inclusion criteria: * patients over 5 kg and less than 18 years of age. * patients having a central venous catheter or cardiac catheterization performed exclusion criteria: * prior history of thrombosis * patients with hemophilia a or b
association of cephalosporin resistance and surgical site infections in patients undergoing pancreaticoduodenectomy

Conditions: Surgical Site Infection; Pancreaticoduodenectomy; Biliary Tract Infection Bacterial

Summary: preoperative biliary drainage predisposes the bile to be contaminated with bacteria of the duodenum. these bacteria colonizing the bile are a potential source for surgical site infections after pancreaticoduodenectomy and many international guidelines recommend the use of cephalosporines as microbial prophylaxis before surgery. the aim of this study was to assess the incidence of bacteria in bile, their resistance profiles and association to surgical site infections in relation to timing of surgery after preoperative biliary drainage in order to better guide antibiotic use.


Eligibility criteria:
inclusion criteria: * all patients undergoing pancreaticoduodenectomy between may 23rd 2016 to october 29th 2020 exclusion criteria: * patients without intraoperative biliary culture * patients with unknown date of preoperative biliary culture
financial distress in advanced cancer patients

Conditions: Advanced Malignant Neoplasm; Locally Advanced Malignant Neoplasm; Metastatic Malignant Neoplasm; Recurrent Malignant Neoplasm; Refractory Malignant Neoplasm

Summary: this trial studies the severity of financial distress in advanced cancer patients. the cost of cancer care can often be very expensive. financial distress from the burdens of high costs and debt may interfere with a patient's physical symptoms and quality of life.

primary objectives: i. to determine the frequency of high financial distress in advanced cancer patients. secondary objectives: i. to determine the association between high financial distress with clinical and demographic characteristics in advanced cancer patients. ii. to determine the correlation between in charge financial distress/ financial well-being scale (ifdfw) and other financial distress instruments such as comprehensive score for financial toxicity-functional assessment of chronic illness therapy (cost-facit) and edmonton symptom assessment scale- financial distress (esas-fs). iii. to determine the association between high financial distress with patient symptoms in esas-fs and quality of life assessed by the functional assessment of cancer therapy - general (fact-g). outline: patients complete questionnaires about financial state and quality of life over 15 minutes. patients' medical chart is also reviewed.

Eligibility criteria:
inclusion criteria: * patient must have a diagnosis of advanced cancer, as defined by recurrent disease, locally advanced disease, metastatic disease, or refractory disease * patients must be able to understand, read, write, and speak english * patients must have no clinical evidence of severe cognitive impairment (memorial delirium assessment scale score of \>= 13) and should be able to consent and answer the questionnaires * patients must sign an informed consent